The Opportunity For You

Market Overview

Market Overview

£135.7 billion

Estimated European Health and Wellbeing Market Value in 2020

(Source: Statista)

£49.52 billion

Medicinal Cannabis: Forecast Medical Cannabis Market Value 2028

(Source: Prohibition Partners)

Medicaleaf™ Forecast

Medicaleaf™ Forecast

From a standing start, MedicaleafTM intends to generate revenue in excess of £5.3 million in this first trading year, with sales increasing by 372% in year two and a further 88% in year three as the ‘demand-supply’ equation is successfully welded.

Financing Required

MedicaleafTM is looking for up to £10 million initial investment. Capital raised will be invested in Product Manufacturing, Sales and Marketing campaigns and distribution infrastructure but will also be used for suitable acquisitions and joint ventures that will catapult the growth of the company in suitable strategic moves.

Such inorganic growth is as yet unknown and as such excluded from any forecasts.

Medicaleaf Limited has achieved EIS Advance Assurance with HMRC so we anticipate eligible investors will be able to gain EIS relief in the current or previous tax year.

MedicaleafTM will have a ‘post-raise’ valuation of £20 million with expectations to reach a pre-floatation valuation of £100 million in three years’ time. New investor capital will represent up to 50% of voting rights.

Exit Strategy

Exit Strategy

Current strategy is to float MedicaleafTM on the Alternative Investment Market in approximately three years’ time when MedicaleafTM share values will have been given a further boost as a result of anticipated liberalization by HM Government of the UK licensing system for Medical Cannabis production and prescription in the UK although a merger with a quoted company cannot be ruled out and will give a speedier exit for investors wishing to do so.

By this time MedicaleafTM will have well-honed brands for both the Medical and Wellness segments of the market and a firm grip of the recognized UK and European Distribution Channels.

EIS Scheme

EIS Scheme

In brief, the Enterprise Investment Scheme (“EIS”) is a Government scheme that is designed to help eligible start-up companies raise finance by offering a range of tax reliefs for investors who subscribe for qualifying shares in qualifying companies.

There are five current EIS tax reliefs available to investors in companies qualifying under the EIS.

30% Income Tax Relief

30% income tax relief on the amount invested provided that the shares are held for a minimum of three years. The maximum amount on which investors may obtain income tax relief can be withdrawn if the investor becomes a ‘Connected Person’ or the company ceases to be qualifying within three years of the share issues.

100% CGT Exemption

CGT exemption on capital gains realised on the disposal of an EIS investment, provided that the shares have been held for at least three years.

Uncapped Cgt Deferral Relief

Unlimited capital gains tax (CGT) deferral providing the investment is made in the period beginning 12 months before and ending 3 years after the date of the disposal subject to CGT. (N.B deferral relief can only be used in lieu of CGT exemption).

100% IHT Exemption

Inheritance Tax (IHT) exemption providing the shares have been held at least two years from the date of issue and are held at the time of death.

Up To 45% Loss Relief Available

Losses on the disposal of shares can be offset against either taxable income or chargeable gains on other assets.

Get Your Download Investors' Memorandum

If you would like to find out more and download our Investors’ Memorandum, we’d love to hear from you.Contact Us
Copyright All Right Reserved Medicaleaf | Privacy Notice | Website by Plan B Creative